Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biopharma IPOs Start To Gear Up For 2013 After A Lull

Executive Summary

Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.

You may also be interested in...



J.P. Morgan Notebook: Tuesday January 14

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the second day of the 2014 J.P. Morgan health care conference, including news from ZS Pharma, Aisling Capital, Astellas, and Moderna.

With A Drug On The Fast Track, Chimerix Aims To Go Public

Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.

Financings Of The Fortnight Ponders Sequester Fallout Potential For Biotech

Plus news on recent financings by Tesaro, Ablynx, Spring Bank Pharmaceuticals and Daiichi Sankyo.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS055042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel